


## **Supplemental Methods**

### **Reactome pathways**

Genes related to a taxonomic identifier (*Homo sapiens*: tax id = 9606) were used exclusively and without literature extension by orthology. To integrate these genes/proteins into molecular pathways of NAFLD, we used the overrepresentation test provided by the PANTHER resource using as input list ('reference' list) the terms retrieved from data mining. We identified 344 Reactome pathways enriched with NAFLD-terms with *p* values that ranged from 4.92E-2 to 5.43E-76. We used WebGestalt (WEB-based Gene SeTAnaLysis Toolkit) functional enrichment analysis (99) available at <http://webgestalt.org/>.

### Reactome pathway of the list of genes causing monogenic disorders associated with liver steatosis



## **Supplemental Figure 1**

Reactome pathway analysis of genes causing monogenic disorders with hepatic steatosis.

Enrichment method: ORA (over-representation analysis). Enrichment Categories: pathway\_Reactome (data source: <https://www.reactome.org/> and <http://www.geneontology.org>). Reference list: list of genes associated with fatty infiltration of liver, Fatty liver, Steatosis, Liver steatosis" (HP:0001397). Cross References: SNOMEDCT\_US:197321007, UMLS:C2711227, SNOMEDCT\_US:442191002, MSH:D005234 in the Human Phenotype Ontology (<https://hpo.jax.org/> . Organism: Homo sapiens. FDR Method: Benjamini-Hochberg. The size and color of the dot is proportional to the number of overlapping (for ORA) or leading edge genes (for GSEA) of the category. ORA was performed by the WebGestalt (WEB-based Gene SeTAnaLysis Toolkit) functional enrichment analysis web tool available at <http://www.webgestalt.org/>.

**Supplemental Table 1: Hereditary disorders associated with hepatic steatosis.**

DISEASE ID	ASSOCIATED DISEASE NAME	GENE ID
ORPHA:254346	19p13.12 microdeletion syndrome	-
ORPHA:1606	1p36 deletion syndrome	GABRD
		RERE
		PRDM16
		SKI
OMIM:610198	3-methylglutaconic aciduria, Type V	DNAJC19
OMIM:231530	3-hydroxyacyl-coA dehydrogenase deficiency	HADH *
OMIM:210200	3-methylcrotonyl-coA carboxylase 1 deficiency	MCCC1
ORPHA:445038	3-methylglutaconic aciduria type 7	CLPB
ORPHA:79086	Acquired generalized lipodystrophy	-
ORPHA:79087	Acquired partial lipodystrophy	LMNB2
ORPHA:99901	Acyl-coA dehydrogenase 9 deficiency	ACAD9
OMIM:201450	Acyl-coA dehydrogenase, medium-chain deficiency	ACADM
OMIM:201475	Acyl-coA dehydrogenase, very long-chain deficiency	ACADVL
OMIM:300270	Adrenomyodystrophy	-
ORPHA:977	Adrenomyodystrophy	-
ORPHA:139507	African iron overload	-
ORPHA:79085	Akt2-related familial partial lipodystrophy	AKT2 *
ORPHA:404454	Alacrimia-choreoathetosis-liver dysfunction syndrome	NGLY1
ORPHA:64	Alström syndrome	ALMS1 *
OMIM:203800	Alström syndrome	ALMS1 *
OMIM:243910	Arima syndrome	-
ORPHA:91	Aromatase deficiency	CYP19A1 *
ORPHA:79474	Atypical Werner syndrome	LMNA
ORPHA:2137	Autoimmune hepatitis	-

<b>ORPHA:369840</b>	Autosomal recessive limb-girdle muscular dystrophy Type 2	TRAPPC11
<b>ORPHA:280365</b>	Autosomal semi-dominant severe lipodystrophic laminopathy	LMNA
<b>ORPHA:528</b>	Berardinelli-Seip congenital lipodystrophy	BSCL2
		CAV1
		CAVIN1
		AGPAT2
		PPARG *
<b>OMIM:615119</b>	Cardioencephalomyopathy, fatal infantile, due to cytochrome C oxidase deficiency 2	COX15
<b>OMIM:212140</b>	Carnitine deficiency, systemic primary	SLC22A5
<b>OMIM:255120</b>	Carnitine palmitoyltransferase I deficiency	CPT1A *
<b>OMIM:600649</b>	Carnitine palmitoyltransferase II deficiency, infantile	CPT2 *
<b>OMIM:608836</b>	Carnitine palmitoyltransferase II deficiency, lethal neonatal	CPT2 *
<b>OMIM:275630</b>	Chanarin-Dorfman syndrome	ABHD5 *
<b>OMIM:618400</b>	Charcot-Marie-Tooth disease, axonal, type 2ee	MPV17
<b>ORPHA:71</b>	Chylomicron retention Disease	SAR1B
<b>ORPHA:435651</b>	Cidec-related familial partial lipodystrophy	CIDEC *
<b>ORPHA:247585</b>	Citrullinemia type II	SLC25A13*
<b>OMIM:603471</b>	Citrullinemia, type II, adult-onset	SLC25A13*
<b>OMIM:614922</b>	Combined oxidative phosphorylation deficiency 11	RMND1
<b>OMIM:614924</b>	Combined oxidative phosphorylation deficiency 12	EARS2
<b>OMIM:615395</b>	Combined oxidative phosphorylation deficiency 16	MRPL44
<b>OMIM:615595</b>	Combined oxidative phosphorylation deficiency 19	LYRM4
<b>OMIM:615918</b>	Combined oxidative phosphorylation deficiency 21	TARS2
<b>OMIM:616672</b>	Combined oxidative phosphorylation deficiency 27	CARS2
<b>OMIM:617872</b>	Combined oxidative phosphorylation deficiency 34	MRPS7
<b>OMIM:212065</b>	Congenital disorder of glycosylation, type Ia	PMM2

<b>OMIM:614576</b>	Congenital disorder of glycosylation, type Iil	COG6
<b>OMIM:616829</b>	Congenital disorder of glycosylation, type lip	TMEM199
<b>OMIM:614921</b>	Congenital disorder of glycosylation, type It	PGM1
<b>OMIM:261515</b>	D-bifunctional protein deficiency	HSD17B4
<b>ORPHA:300536</b>	DDOST-CDG (Developmental delay, hypotonia, strabismus and hepatic dysfunction DDOST	
<b>ORPHA:66634</b>	Dilated cardiomyopathy with ataxia	DNAJC19
<b>ORPHA:412</b>	Dysbetalipoproteinemia	APOE *
<b>ORPHA:444490</b>	Familial chylomicronemia syndrome	-
<b>ORPHA:2348</b>	Familial partial lipodystrophy, Dunnigan type	LMNA
<b>ORPHA:79084</b>	Familial partial lipodystrophy, Köbberling type	LMNA
<b>OMIM:613282</b>	Fatty liver disease, nonalcoholic, susceptibility to, 1	-
<b>OMIM:613387</b>	Fatty liver disease, nonalcoholic, susceptibility to, 2	-
<b>OMIM:229600</b>	Fructose intolerance, hereditary	ALDOB *
<b>ORPHA:348</b>	Fructose-1,6-bisphosphatase deficiency	FBP1 *
<b>ORPHA:264580</b>	Glycogen storage disease due to liver phosphorylase kinase deficiency	PHKG2
		PHKA2
<b>ORPHA:53693</b>	Gracile syndrome	BCS1L
<b>OMIM:617093</b>	Growth retardation, impaired intellectual development, hypotonia and hepatopath ARS1	
<b>ORPHA:139491</b>	Hemochromatosis type 4	SLC40A1 *
<b>ORPHA:93111</b>	Hnf1b-related autosomal dominant tubulointerstitial kidney disease	HNF4A *
		HNF1B *
<b>OMIM:236200</b>	Homocystinuria due to cystathionine beta-synthase deficiency	CBS *
<b>ORPHA:391665</b>	Homozygous familial hypercholesterolemia	LDLRAP1 *
		LDLR *
		PCSK9 *
		APOB *
		ABCG8 *

		ABCG5 *
<b>ORPHA:740</b>	Hutchinson-Gilford progeria syndrome	LMNA *
		ZMPSTE24
<b>ORPHA:209902</b>	Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency	
<b>ORPHA:71212</b>	Hyperinsulinism due to short chain 3-hydroxylacyl-coA dehydrogenase deficiency	HADH
<b>OMIM:614300</b>	Hypermethioninemia due to adenosine kinase deficiency	ADK
<b>OMIM:614480</b>	Hypertriglyceridemia, transient infantile	GPD1 *
<b>OMIM:300972</b>	Immunodeficiency 47	ATP6AP1
<b>ORPHA:52430</b>	Inclusion body myopathy with Paget disease of bone and frontotemporal dementia	HNRNPA2B1
		HNRNPA1
		VCP
<b>OMIM:615438</b>	Infantile liver failure syndrome 1	LARS1
<b>OMIM:615486</b>	Interstitial lung and liver disease	MARS1
<b>OMIM:220111</b>	Leigh syndrome, French Canadian type	LRPPRC
<b>ORPHA:435660</b>	LIPE-related familial partial lipodystrophy	LIPE *
<b>ORPHA:156156</b>	Lipoatrophy with diabetes, leukomelanodermic papules, liver steatosis, and hypertrophic cardiomyopathy	-
<b>OMIM:608594</b>	Lipodystrophy, congenital generalized, type 1	AGPAT2 *
<b>OMIM:269700</b>	Lipodystrophy, congenital generalized, type 2	BSCL2
<b>OMIM:612526</b>	Lipodystrophy, congenital generalized, type 3	CAV1 *
<b>OMIM:613327</b>	Lipodystrophy, congenital generalized, type 4	CAVIN1
<b>OMIM:151660</b>	Lipodystrophy, familial partial, type 2	LMNA
<b>OMIM:604367</b>	Lipodystrophy, familial partial type 3	PPARG
<b>OMIM:613877</b>	Lipodystrophy, familial partial type 4	PLIN1 *
<b>OMIM:615238</b>	Lipodystrophy, familial partial, type 5	CIDEc
<b>OMIM:615980</b>	Lipodystrophy, familial partial, type 6	LIPE
<b>OMIM:613070</b>	Liver failure, infantile, transient	TRMU

<b>ORPHA:99900</b>	Long chain acyl-coA dehydrogenase deficiency	-
<b>ORPHA:275761</b>	Lysosomal acid lipase deficiency	-
<b>OMIM:278000</b>	Lysosomal acid lipase deficiency	LIPA *
<b>OMIM:615381</b>	Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome	POLD1
<b>ORPHA:42</b>	Medium chain acyl-coA dehydrogenase deficiency	ACADM
<b>ORPHA:436182</b>	Microcephalic primordial dwarfism-insulin resistance Syndrome	NSMCE2 XRCC4
<b>OMIM:611126</b>	Mitochondrial complex I deficiency due to Acad9 deficiency	ACAD9
<b>OMIM:618234</b>	Mitochondrial complex I deficiency, nuclear type 11	NDUFAF1
<b>OMIM:124000</b>	Mitochondrial complex III deficiency, nuclear type 1	BCS1L
<b>OMIM:617156</b>	Mitochondrial DNA depletion syndrome 15 (hepatocerebral Type)	TFAM
<b>OMIM:251880</b>	Mitochondrial DNA depletion syndrome 3 (hepatocerebral Type)	DGUOK *
<b>OMIM:203700</b>	Mitochondrial DNA depletion syndrome 4a (Alpers Type)	POLG
<b>ORPHA:298</b>	Mitochondrial neurogastrointestinal encephalomyopathy	POLG RRM2B TYMP
<b>ORPHA:746</b>	Mitochondrial trifunctional protein deficiency	HADHA HADHB
<b>ORPHA:96168</b>	Monosomy 13q34	-
<b>ORPHA:99226</b>	Monosomy X	-
<b>OMIM:615703</b>	Morbid obesity and spermatogenic failure	CEP19
<b>ORPHA:99228</b>	Mosaic monosomy X	-
<b>OMIM:617303</b>	Mucopolysaccharidosis-plus syndrome	VPS33A
<b>OMIM:231680</b>	Multiple acyl-coA dehydrogenase deficiency	ETFB ETFA ETFDH

<b>OMIM:615356</b>	Muscular dystrophy, limb-girdle, autosomal Recessive 18	TRAPP C11
<b>OMIM:256810</b>	Navajo neurohepatopathy	MPV17
<b>ORPHA:247598</b>	Neonatal intrahepatic cholestasis due To citrin deficiency	SLC25A13
<b>OMIM:616263</b>	Neurologic, endocrine and pancreatic disease, multisystem, infantile-onset	PTRH2
<b>ORPHA:98907</b>	Neutral lipid storage disease with ichthyosis	ABHD5
<b>OMIM:610717</b>	Neutral lipid storage disease with myopathy	PNPLA2 *
<b>ORPHA:98908</b>	Neutral lipid storage myopathy	PNPLA2
<b>ORPHA:436271</b>	Non-progressive predominantly posterior cavitating leukoencephalopathy with peripheral neuropathy	COA8
<b>OMIM:601466</b>	Patent ductus venosus	-
<b>OMIM:264470</b>	Peroxisomal acyl-coA oxidase deficiency	ACOX1
<b>OMIM:261650</b>	Phosphoenolpyruvate carboxykinase 2, mitochondrial	PCK2 *
<b>OMIM:261680</b>	Phosphoenolpyruvate carboxykinase deficiency, cytosolic	PCK1 *
<b>ORPHA:280356</b>	Plin1-related familial partial lipodystrophy	PLIN1
<b>ORPHA:101330</b>	Porphyria cutanea tarda	-
<b>ORPHA:79083</b>	Pparg-related familial partial lipodystrophy	PPARG
<b>ORPHA:90970</b>	Primary lipodystrophy	-
<b>ORPHA:2959</b>	Progeria-short stature-pigmented nevi syndrome	-
<b>OMIM:613658</b>	Rajab interstitial lung disease with brain calcifications	FARS2
<b>OMIM:617253</b>	Seckel syndrome 10	NSMCE2
<b>ORPHA:363400</b>	Severe neurodegenerative syndrome with lipodystrophy	BSCL2 *
<b>ORPHA:465508</b>	Symptomatic Form of hemochromatosis type 1	HFE *
<b>ORPHA:881</b>	Turner syndrome	-
<b>ORPHA:99413</b>	Turner syndrome due to structural X chromosome anomalies	-
<b>OMIM:228100</b>	Visceral steatosis, congenital	-
<b>ORPHA:3455</b>	Wiedemann-Rautenstrauch syndrome	POLR3A

ORPHA:905

Wilson disease

ATP7B

This search was performed using The Human Phenotype Ontology (<https://hpo.jax.org/>) database, which contains 3,000 terms and over 156,000 annotations to hereditary diseases. We searched for disease terms: "Fatty infiltration of liver, Fatty liver, Steatosis, Liver steatosis" Hepatic steatosis HP:0001397. Cross References: *SNOMEDCT\_US:197321007, UMLS:C2711227, SNOMEDCT\_US:442191002, MSH:D005234*. Source of disease ID: Orphanet, DECIPHER, and OMIM. \*

The list includes genes associated with the pathogenesis of NAFLD identified in previous human studies and are included in the enrichment analysis.